сгенерировать QR код
Открытый доступ
Только для подписчиков
Экстракорпоральные методы гемокоррекции при заболеваниях почек (обзор литературы)
https://doi.org/10.36485/1561-6274-2024-28-4-9-21
EDN: QUMKLQ
Аннотация
Обзор литературы посвящен методам экстракорпоральной гемокоррекции, таким как плазмаобмен, каскадная плазмафильтрация и иммуносорбция при заболеваниях почек, включая гломерулонефрит, ассоциированный с антителами к базальной мембране клубочка, гломерулонефрит, ассоциированный с антинейтрофильными цитоплазматическими антителами, фокально-сегментарный гломерулосклероз, системная красная волчанка, атипичный гемолитикоуремический синдром у взрослых
Об авторе
А. М. Фомин
Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского
Россия
Россия
Проф. Фомин Александр Михайлович, д-р мед наук, отделение хирургической гемокоррекции и детоксикации, ведущий научный сотрудник
120110, Москва, ул. Щепкина, д. 61/2, корп 9
Список литературы
1. Connelly-Smith L, Alquist CR, Aqui NA et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidencebased approach from th writing committee of the American Society for Apheresis: the Ninth special issue. J Clin Apher 2023;38:77– 278. doi: 10.1002/jca.22043
2. Williams ME, Balogun RA. Principles of separation:indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol 2014;9(1):181–190. doi: 10.2215/CJN.04680513
3. Pusey CD, Levy JB. Plasmapheresis in immunologic renal disease. Blood Purif 2012;33(1-3):190–198. doi: 10.1159/000334155
4. Hafer C, Golla P, Gericke M et al. Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Int UrolNephrol 2016;48(1):133–138. doi: 10.1007/s11255-015-1137-3
5. Yamaji K. Immunoadsorption for collagen and rheumatic diseases. Transfusion and Apheresis Science 2017;56(5):666– 670. doi: 10.1016/j.transci.2017.08.012
6. Hirano R, Namazuda K, Hirata N. Double filtration plasmapheresis: review of current clinical applications. Ther Apher Dial 2021;25(2):145–151. doi: 10.1111/1744-9987.13548
7. Poullin P, Announ N, Mugnier B et al. Protein A-immunoadsorption (prosorba column) in the treatment of rheumatoid arthritis. Joint Bone Spine 2005;72(2):101–103. doi: 10.1016/j.jbspin.2004.02.009
8. Соколов АА, Мануилов АС, Бардаков СН и др. Программная иммуносорбция с регенерацией сорбционных колонок при лечении волчаночного нефрита. Современная ревматология 2020;14(3):111–116. doi: 10.14412/1996-7012-2020-3-111-116
9. Новые колонки. Брендбук. ООО «НПФ Покард». 16с. Интернет ресурс https://pocard.ru/wp-content/uploads/Broshures/1.%20Брендбук_новые_колонки.pdf
10. Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1–11. doi: 10.1002/ art.37715. doi: 10.1002/art.37715
11. Kalluri R, Wilson CB, Weber M et al. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and goodpasture syndrome. J Am Soc Nephrol 1995;6(4):1178–1185. doi: 10.1681/ASN.V641178
12. Levy JB, Hammad T, Coulthart A et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004;66(4):1535–1540. doi: 10.1111/j.15231755.2004.00917.x
13. Johnson JP, Moore J, Austin HA et al. Therapy of antiglomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors. Med (United States) 1985;64(4):219–227. doi: 10.1097/00005792-198507000-00003
14. Kaewput W, Thongprayoon C, Boonpheng B et al. In patient burden and mortality of Goodpasture's syndrome in the United States:nationwide inpatient sample 2003–2014. J Clin Med 2020;9:455. doi: 10.3390/jcm9020455
15. Marques C, Carvelli J, Biard L et al. Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients. Front Immunol 2019;10. doi: 10.3389/fimmu.2019.01665
16. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001;134(11):1033–1042. doi: 10.7326/0003-4819-134-11200106050-00009
17. Rovin BH, Adler SG, Barratt J et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:753–779. doi: 10.1016/j.kint.2021.05.015
18. Lockwood CM, Boulton-Jones JM, Lowenthal RM et al. Recovery from goodpasture’s syndrome after immunosuppressive treatment and plasmapheresis. Br Med J 1975;2(5965):252–254. doi: 10.1136/bmj.2.5965.252
19. Savage CO, Pusey CD, Bowman C et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980–4. Br Med J (Clin Res Ed) 1986;292:301–304. doi: 10.1136/bmj.292.6516.301
20. Hu W, Liu Z, Ji D et al. Staphylococcal protein a immunoadsorption for goodpasture’s syndrome in four chinese patients. Journal of Nephrology 2006;19(3):312–317
21. Laczika K, Knapp S, Derfler K et al. Immunoadsorption in goodpasture’s syndrome. Am J Kidney Dis 2000;36(2):392–395. doi: 10.1053/ajkd.2000.8993
22. Biesenbach P, Kain R, Derfler K et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption. PLoS One 2014;9(7):e103568. doi: 10.1371/journal.pone.0103568
23. Zhang Y-y, Tang Z, Chen D-M et al. Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol 2014;15:128. doi: 10.1186/1471-2369-15-128
24. Beck LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361(1):11–21. doi: 10.1056/NEJMoa0810457
25. Tomas NM, Beck LH, Meyer-Schwesinger C et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371(24):2277–2287. doi: 10.1056/NEJMoa1409354
26. Sethi S, Debiec H, Madden B et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 2020;97(1):163–174. doi: 10.1016/j.kint.2019.09.014
27. Sethi S, Madden BJ, Debiec H et al. Exostosin 1/exostosin 2-associated membranous nephropathy. J Am Soc Nephrol 2019;30(6):1123–1136. doi: 10.1681/ASN.2018080852
28. Xu Z, Chen L, Xiang H et al. Advances in Pathogenesis of Idiopathic Membranous Nephropathy. Kidney Dis 2020:330–345. doi: 10.1159/00050770
29. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year followup of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48(5):1600–1604. doi: 10.1038/ki.1995.453
30. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59(4):1484–1490. doi: 10.1046/j. 1523-1755.2001.0590041484.x
31. Beck L, Bomback AS, Choi MJ et al. KDOQI US commentary on the 2012 KDI-GO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 2013;62(3):403–441. doi: 10.1053/j.ajkd.2013.06.002
32. Perna A, Schieppati A, Zamora J et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004;44(3):385–401. doi: 10.1053/j.ajkd.2004.05.020
33. Muller-Deile J, Schiffer L, Hiss M et al. A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. Eur J Clin Invest 2015;45(12):1260– 1269. doi: 10.1111/eci.12545
34. Esnault VL, Besnier D, Testa A et al. Effect of protein a immunoadsorption in nephrotic syndrome of various etiologies. J Am Soc Nephrol 1999;10(9):2014–2017. doi: 10.1681/ASN.V1092014
35. Hamilton P, Kanigicherla D, Hanumapura P et al. Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy. J Clin Apher 2018;33(3):283–290. doi: 10.1002/jca.21599
36. Eskandary F, Wahrmann M, Biesenbach P et al. ABO antibody and complement depletion by immunoadsorption combined with membrane filtration a randomized, controlled, cross-over trial. Nephrol Dial Transplant 2014;29(3):706–714. doi: 10.1093/ndt/gft502
37. Weinmann-Menke J, Holtz S, Sollinger D et al. Treatment of membranous nephropathy in patients with THSD7A antibodies using immunoadsorption. Am J Kidney Dis 2019;74(6):849–852. doi: 10.1053/j.ajkd.2019.05.021
38. Konigshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: areview of proposed candidates. Biomed Res Int 2016;2016:3765608. doi: 10.1155/2016/3765608
39. Kashgary A, Sontrop J, Li L et al. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrology 2016;17:104. doi: 10.1186/s12882-016-0322-7
40. Ren H, Shen P, Li X et al. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. Am J Nephrol 2013;37(1):84–90. doi: 10.1159/000346256
41. Beer A, Mayer G, Kronbichler A. Treatment strategies of adult primary focal segmental glomerulosclerosis: a systematic review focusing on the last two decades. Biomed Res Int 2016;2016:4192578. doi: 10.1155/2016/4192578
42. Lau EW, Ma PH, Wu X et al. Mycophenolate mofetil for pri mary focal segmental glomerulosclerosis: systematic review. Ren Fail 2013;35(6):914–929. doi: 10.3109/0886022X.2013.794687
43. Hansrivijit P, Cheungpasitporn W, Thongprayoon C et al. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. BMC Nephrol 2020;21(1):134. doi: 10.1186/s12882-020-01797-7
44. Korbet SM. The treatment of primary focal segmental glomerulosclerosis. Ren Fail 2000;22(6):685–696. doi: 10.1081/jdi-100101956
45. Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 1998;13(6):1524–1528. doi: 10.1093/ndt/13.6.1524
46. Moriconi L, Lenti C, Puccini R et al. Proteinuria in focal segmental glomerulosclerosis: role of circulating factors and therapeutic approach. Ren Fail 2001;23(3-4):533–541. doi: 10.1081/jdi-100104735
47. Muso E, Mune M, Hirano T et al. A prospective observational survey on the long-term effect of LDL apheresis on drugresistant nephrotic syndrome. Nephron Extra 2015;5(2):58–66. doi: 10.1159/000437338
48. Dirim AB, Demir E, Guller N et al. Efficacy of intravenous combined immunosuppression with plasmapheresis in adult patients with refractory primary focal segmental glomerulosclerosis. J Clin Apher 2022;37:376–387. doi: 10.1002/jca.21985
49. Fencl F, Vondrak K, Rosik T et al. Recurrence of nephrotic proteinuria in children with focal segmental glomoerulosclerosis: early treatment with plasmapheresis and immunoasorption should be associated with better prognosis. Minerva Pediatrica 2016;68:348–335
50. Uffing A, Perez-Saez MJ, Mazzali M et al. Recurrence of FSGS after kidney transplantation in adults. Clin J Am Soc Nephrol 2020;15:247–325. doi: 10.2215/CJN.08970719
51. Raina R, Krishnappa V, Sanchez-Kazi C et al. Dextransulfate plasma adsorption lipoprotein apheresis in drug resistant primary focal segmental glomerulosclerosis patients: results from a prospective, multicenter, single-arm intervention study. Front Pediatr 2019;7:454. doi: 10.3389/fped.2019.00454
52. Nakazawa D, Masuda S, Tomaru U et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 2019;15(2):91–101. doi: 10.1038/s41584-018-0145-y
53. Yang JJ, Jennette JC, Falk RJ. Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase. Clin Exp Immunol 1994;97(3):466–473. doi: 10.1111/j.1365-2249.1994.tb06111.x
54. Pusey CD, Rees AJ, Evans DJ et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757–763. doi: 10.1038/ki.1991.272
55. Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18(7):2180–2188. doi: 10.1681/ASN.2007010090
56. Walsh M, Casian A, Flossmann O et al. Long-term followup of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013;84:397–402. doi: 10.1038/ki.2013.131
57. Walsh M, Merkel PA, Peh CA et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis (PEXIVAS). N Engl J Med 2020;382(7):622–631. doi: 10.1056/NEJMoa1803537
58. Derebail VK, Falk RJ. ANCA-associated vasculitis – refining therapy with plasma exchange and glucocorticoids. N Engl J Med 2020;382:671–673. doi: 10.1056/NEJMe1917490
59. Walsh M, Collister D, Zeng L et al. The effects of plasma exchange inpatients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ 2022;376:e064604. doi: 10.1136/bmj-2021-064604
60. Bellos I, Michelakis I, Nikolopoulos D. The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Clinical Rheumatology 2020;40(4):1447– 1456. doi: 10.1007/s10067-020-05390-z
61. Клинические практические рекомендации KDIGO 2021 по лечению гломерулярных болезней. Бобкова ИН, Буланов НМ, Захарова ЕВ и др., под общей редакцией ЕВ Захаровой. Нефрология и диализ 2022;24(4):577–874. doi: 10.28996/2618-9801-2022-4-577-874
62. Palmer A, Cairns T, Dische F et al. Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 1991;6(8):536–542. doi: 10.1093/ndt/6.8.536
63. Esnault VL, Testa A, Jayne DR et al. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 1993;65:180–184. doi: 10.1159/000187471
64. Matic G, Michelsen A, Hofmann D et al. Three Cases of C-ANCA-Positive Vasculitis Treated with Immunoadsorption: Possible Benefit in Early Treatment. Therapeutic Apheresis and Dialysis 2001;5(1):68–72. doi: 10.1046/j.1526-0968.2001.005001068.x
65. Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 2018;13(2):300–317
66. Soejima K, Mimura N, Hirashima M et al. A novel human metalloprotease synthe-sized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem 2001;130(4):475–480. doi: 10.1093/oxfordjournals.jbchem.a003009
67. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara medical university during 1998 – 2008. Intern Med 2010;49(1):7–15. doi: 10.2169/internalmedicine.49.2706
68. Scully M, Hunt BJ, Benjamin S et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012;158(3):323–335. doi: 10.1111/j.1365-2141.2012.09167.x
69. Sarode R, Bandarenko N, Brecher ME et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014;29(3):148–167. doi: 10.1002/jca.21302
70. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325(6):393–397. doi: 10.1056/NEJM199108083250604
71. Coppo P, Bussel A, Charrier S et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 2003;82:27–38. doi: 10.1097/00005792200301000-00003
72. Raval JS, Mazepa MA, Rollins-Raval MA et al. Therapeutic plasma exchange taper does not decrease exacerbations in immune thrombotic thrombocytopenic purpura patients. Transfusion 2020;60:1676–1680. doi: 10.1111/trf.15901
73. van Dorland HA, Taleghani MM, Sakai K et al. The international hereditary thrombotic thrombocytopenic purpura registry: key findings at enrollment until 2017. Haematologica 2019;104(10):2107–2115. doi: 10.3324/haematol.2019.216796
74. Cataland SR, Kourlas PJ, Yang S et al. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura Blood Adv 2017;1(23):2075–2082. doi: 10.1182/bloodadvances.2017009308
75. Scully M, Cataland SR, Peyvandi F et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019;380(4):335–346. doi: 10.1056/NEJMoa1806311
76. Knobl P, Haas M, Laczika K et al. Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13. J Thromb Haemost 2003;1(1):187–189. doi: 10.1046/j.1538-7836.2003.00004.x
77. Drew MJ. Resolution of refractory, classic thrombotic thrombocytopenic purpura after staphylococcal protein a immunoadsorption. Transfusion 1994;34(6):536–538. doi: 10.1046/j.1537-2995.1994.34694295072.x
78. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365(9464):1073–1086. doi: 10.1016/S01406736(05)71144-2
79. Syed S, Hakala P, Singh AK et al. Role of pneumococcal NanA neuraminidase activity in peripheral blood. Front Cell Infect Microbiol 2019;9:218. doi: 10.3389/fcimb.2019.00218
80. Nathanson S, Kwon T, Elmaleh M et al. Acute neurological involvement in diarrhea associ[ated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2010;5:1218–1228. doi: 10.2215/CJN.08921209
81. Menne J, Nitschke M, Stingele R et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012;345:e4565. doi: 10.1136/bmj.e4565
82. Waters AM, Kerecuk L, Luk D et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr 2007;151:140–144. doi: 10.1016/j.jpeds.2007.03.055.
83. Greinacher A, Friesecke S, Abel P et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011;378(9797):1166–1173. doi: 10.1016/S01406736(11)61253-1
84. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361(17):1676–1687. doi: 10.1056/ NEJMra0902814
85. Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2018;34:1337–1348. doi: 10.1007/s00467-018-4039-7
86. Fremeaux-Bacchi V, Miller EC, Liszewski MK et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008;112(13):4948–4952. doi: 10.1182/blood-2008-01-133702
87. Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolyticuremic syndrome. N Engl J Med 2009;361(4):345–357. doi: 10.1056/NEJMoa0810739
88. Jozsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/ CFHR3 deficiency. Blood 2008;111(3):1512–1514. doi: 10.1182/blood-2007-09-109876
89. Bayer G, von Tokarski F, Thoreau B et al. Etiologyand outcomes of thrombotic microangiopathies. CJASN 2019;14(4):557– 566. doi: 10.2215/CJN.11470918
90. Fakhouri F, Hourmant M, Campistol JM et al. Terminal complement inhibitor eculizumab in adultpatients with atypical hemolytic uremic syndrome: a Single-Arm, OpenLabel trial. Am J Kidney Dis 2016;68(1):84–93. doi: 10.1053/j.ajkd.2015.12.034
91. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5(10):1844–1859. doi: 10.2215/CJN.02210310
92. Cao M, Leite BN, Ferreiro T et al. Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury. Am J Nephrol 2018;48(3):225–233. doi: 10.1159/000492865
93. Боброва ЛА, Ватазин АВ, Демьянова КА и др. Атипичный гемолитико-уремический синдром». Клинические рекомендации, 2021. https://cr.minzdrav.gov.ru/recomend/550_2
94. Mannik M, Merrill CE, Stamps LD et al. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003;30(7):1495–1504.
95. Hohenstein B, Bornstein SR, Aringer M. Immunoadsorption for connective tissue disease. Atheroscler Suppl 2013;14(1):185. doi: 10.1016/j.atherosclerosissup.2012.10.034
96. Jones JV, Cumming RH, Bucknall RC et al. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976;1(7962):709–711. doi: 10.1016/s0140-6736(76)93088-9
97. Lewis EJ, Hunsicker LG, Lan SP et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The lupus nephritis collaborative study group. N Engl J Med 1992;326(21):1373– 1379. doi: 10.1056/NEJM199205213262101
98. Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheumat 1998;41(3):414–420
99. Soyuoz A, Karadag O, Karaagac T et al. Therapeutic plasma exchange for refractory SLE: a comparison of outcomes between different sub-phenotypes. Eur J Rheumatol 2018;5(1):32–36. doi: 10.5152/eurjrheum.2017.17088
100. Li QY, Yu F, Zhou FD, Zhao MH. Plasmapheresis Is Associated With Better Renal Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A Case Series Study. Medicine (Baltimore) 2016;95:e3595. doi: 10.1097/MD.0000000000003595
101. Gordon C, Amissah-Arthur MB, Gayed M et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 2018;57:e1– e45. doi: 10.1093/rheumatology/kex286
102. Федеральные клинические рекомендации по диагностике и лечению системной красной волчанки. Ассоциация ревматологов России. 2016 г. – 24с Интернет ресурс: https://rheumatolog.ru/sites/default/files/Pdf/clinrec/sistemnaya_krasnaya_volchanka_do
103. Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003;7:173–182. doi: 10.1046/j.1526-0968.2003.00032.x
104. Fanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Reanal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713–723. doi: 10.1136/annrheumdis-2020-216924
105. Stummvoll G, Aringer M, Handisurya A et al. Immunoadsorption in autoimmune diseases affecting the kidney. Semin Nephrol 2017;37(5):478–487. doi: 10.1016/j.semnephrol.2017.05.020
106. Stummvoll GH, Aringer M, Smolen JS et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 2005;64(7):1015–1021. doi: 10.1136/ard.2004.029660
107. Gaubitz M, Seidel M, Kummer S et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 1998;11(5):495–501. doi: 10.1006/jaut.1998.0229
108. Yang M, Liao C, Zhu Q et al. Meta-analysis on the efficacy and safety of immunoadsorption for systemic lupus erythematosus among Chinese population. Clin Rheumatol 2020;39:3581–3592. doi: 10.1007/s10067-020-05156-7
Рецензия
Для цитирования:
Фомин А.М. Экстракорпоральные методы гемокоррекции при заболеваниях почек (обзор литературы). Нефрология. 2024;28(4):9-21. https://doi.org/10.36485/1561-6274-2024-28-4-9-21. EDN: QUMKLQ
For citation:
Fomin A.M. Extracorporeal methods of hemocorrection in kidney diseases (literature review). Nephrology (Saint-Petersburg). 2024;28(4):9-21. (In Russ.) https://doi.org/10.36485/1561-6274-2024-28-4-9-21. EDN: QUMKLQ
Просмотров:
149
Послать статью по эл. почте 